What it's for (Indications)
- Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor indicated for the symptomatic relief in the treatment of various inflammatory and painful conditions.
- Its primary applications include the management of chronic conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS).
- It is also prescribed for the short-term treatment of acute pain, including acute gouty arthritis, primary dysmenorrhea, and acute pain following dental surgery.
- The selection of etoricoxib for specific indications is often guided by its favorable gastrointestinal safety profile compared to non-selective NSAIDs, particularly in patients at increased risk for gastrointestinal complications, though careful consideration of cardiovascular risks is paramount.
- This drug is utilized to reduce inflammation and alleviate pain, improving patient mobility and quality of life in appropriate clinical scenarios.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of etoricoxib is highly individualized based on the specific indication, patient response, and tolerance, always aiming for the lowest effective dose for the shortest possible duration. For osteoarthritis, the typical recommended dose is 30 mg or 60 mg once daily. For rheumatoid arthritis, ankylosing spondylitis, and chronic low back pain, a dose of 60 mg or 90 mg once daily is generally prescribed. In acute gouty arthritis, a higher dose of 120 mg once daily may be used for a maximum of 8 days. For acute pain, such as post-operative dental pain or primary dysmenorrhea, 90 mg or 120 mg once daily is administered for a limited duration. The maximum recommended daily dose for any indication should not exceed 120 mg. Dosage adjustments may be necessary in patients with hepatic impairment, and the drug is contraindicated in severe hepatic or renal dysfunction. |
Safety & Warnings
Common Side Effects
- The use of etoricoxib can be associated with a range of adverse effects, some of which can be serious.
- Cardiovascular events are a significant concern, including an increased risk of myocardial infarction, stroke, and new-onset or worsening hypertension, as well as peripheral edema and fluid retention.
- Gastrointestinal side effects, while generally lower than non-selective NSAIDs, still include the potential for serious events such as ulceration, bleeding, and perforation of the stomach or intestines.
- Other common adverse effects may involve dizziness, headache, fatigue, palpitations, and gastrointestinal symptoms like abdominal pain, dyspepsia, nausea, and diarrhea.
- Less commonly, patients may experience renal impairment, elevated liver enzymes, hypersensitivity reactions (e.
- g.
- , rash, angioedema), and bronchospasm in susceptible individuals.
- Vigilant monitoring for these adverse effects is crucial during therapy.
Serious Warnings
- Black Box Warning: Etoricoxib, belonging to the class of selective cyclooxygenase-2 (COX-2) inhibitors, carries significant and serious risks similar to other non-steroidal anti-inflammatory drugs (NSAIDs), necessitating stringent warnings. Although not formally designated with an FDA Black Box Warning due to its non-approval status in the United States, international regulatory bodies and clinical experience highlight two primary areas of serious concern: **1. Cardiovascular Thrombotic Events:** NSAIDs, including etoricoxib, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may manifest early in the treatment course and may increase with duration of use. Patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Etoricoxib is explicitly contraindicated in patients with established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease, and in those with moderate to severe congestive heart failure (NYHA Class II-IV). Healthcare providers must carefully assess a patient's cardiovascular risk factors before prescribing and throughout the course of treatment. **2. Gastrointestinal Risk:** NSAIDs, including etoricoxib, cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events. Although selective COX-2 inhibitors may have a lower GI risk compared to non-selective NSAIDs, this risk is not eliminated. Careful monitoring for signs and symptoms of GI bleeding or ulceration is essential, and co-administration with protective agents like proton pump inhibitors should be considered for high-risk individuals.
- Etoricoxib, like other NSAIDs, carries several important warnings.
- A primary concern is its association with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
- This risk may increase with higher doses and longer durations of treatment, and patients with pre-existing cardiovascular conditions are particularly vulnerable.
- Hypertension must be carefully monitored, as etoricoxib can exacerbate or induce new-onset hypertension.
- Serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, can occur at any time without warning symptoms.
- Renal toxicity, including acute renal failure, fluid retention, and edema, is another significant risk, particularly in patients with pre-existing renal impairment, heart failure, or dehydration.
- Hepatic adverse reactions, some severe, have been reported.
- Etoricoxib should be used with extreme caution in patients with a history of asthma, as it can precipitate bronchospasm.
How it Works (Mechanism of Action)
Etoricoxib exerts its therapeutic effects primarily through the selective inhibition of cyclooxygenase-2 (COX-2) enzyme. Cyclooxygenase enzymes are crucial in the synthesis of prostaglandins from arachidonic acid, which are lipid mediators involved in inflammation, pain, and fever. Unlike non-selective NSAIDs that inhibit both COX-1 and COX-2, etoricoxib preferentially inhibits COX-2. COX-2 is primarily induced at sites of inflammation and pain, while COX-1 is constitutively expressed and plays a vital role in maintaining gastrointestinal mucosal integrity, renal blood flow, and platelet aggregation. By selectively inhibiting COX-2, etoricoxib aims to reduce inflammatory processes and pain transmission while theoretically minimizing COX-1 mediated side effects, particularly those affecting the gastrointestinal tract. This mechanism underpinning its anti-inflammatory, analgesic, and antipyretic properties, making it effective in managing various painful and inflammatory conditions.